13849-32-6

Basic information

• Product Name: 3,4-dihydro-2H-1-Benzopyran-5-ol
• Synonyms: 3,4-dihydro-2H-1-Benzopyran-5-ol;3,4-dihydro-2H-chroMen-5-ol
• CAS NO: 13849-32-6
• Molecular Formula: C₉H₁₀O₂
• Molecular Weight: 150.17
• Mol File: 13849-32-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 273.5±29.0 °C(Predicted)
• Appearance: /
• Density: 1.194±0.06 g/cm3(Predicted)
• PKA: 10.11±0.20(Predicted)
• CAS DataBase Reference: 3,4-dihydro-2H-1-Benzopyran-5-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-dihydro-2H-1-Benzopyran-5-ol(13849-32-6)
• EPA Substance Registry System: 3,4-dihydro-2H-1-Benzopyran-5-ol(13849-32-6)

Safety Data

• Hazardous Substances Data: 13849-32-6(Hazardous Substances Data)

Usage

Uses

3,4-Dihydro-2H-1-benzopyran-5-ol is used in preparation of thiazolylmethylthioarylacetates and related compounds as modulators of peroxisome proliferator activating receptor (PPAR) activity.

Upstream product

• 3722-77-8 3,4-dihydro-5-methoxy-2H-chromene 
• 3952-69-0 5-hydroxy-4H-1-benzopyran-4-one 
• 319478-14-3 5-bromochromane 
• 41389-15-5 2-allyl-3-bromophenol 
• 41388-50-5 1-(allyloxy)-3-bromobenzene 
• 591-20-8 3-Bromophenol 
• 41580-69-2 5-methoxybenzopyran 

Downstream Products

• 613240-81-6 {8-[4-(4-Trifluoromethyl-benzyloxy)-benzylsulfanyl]-chroman-5-yloxy}-acetic Acid Methyl Ester 

Relevant articles and documents

Ether compound and pharmaceutical application thereof in prevention and treatment of diabetes and metabolic syndrome

The invention relates to an ether compound and a pharmaceutical application thereof in prevention and treatment of diabetes and metabolic syndrome. Specifically, the invention provides a compound as shown in a formula (I), an isomer, a raceme, a prodrug, a solvate, a deuterated substance or a pharmaceutically acceptable salt thereof, and Ar1, Ar2, X, Y and R are defined in the specification.

Compounds that modulate PPAR activity and methods of preparation

This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.